Tags: Drug.

Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-13-glucan an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16 2005 and gained approval in the European Union on April 25 2008.

Micafungin.svg
ATC prefix
J02
ATC suffix
AX05
CAS number
235114-32-6
DrugBank
DB01141
FDA UNII code
R10H71BSWG
IUPAC name
5-[(1S2S)-2-[(3S6S9S11R15S18S20R21R24S25S26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11202125-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-258141723-hexaoxo-18-[(4-5-[4-(pentyloxy)phenyl]-12-oxazol-3-ylbenzene)amido]-147131622-hexaazatricyclo[22.3.0.0913]heptacosan-6-yl]-12-dihydroxyethyl]-2-hydroxyphenyloxidanesulfonic acid
PubChem
477468

Loading...

This page contains content from the copyrighted Wikipedia article "Micafungin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.